Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 0.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,714,845 shares of the company’s stock after purchasing an additional 22,804 shares during the quarter. Vanguard Group Inc. owned 5.60% of Nurix Therapeutics worth $21,339,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. raised its holdings in Nurix Therapeutics by 5.3% in the 2nd quarter. BlackRock Inc. now owns 4,519,377 shares of the company’s stock worth $45,149,000 after purchasing an additional 228,237 shares during the period. Wasatch Advisors LP raised its holdings in shares of Nurix Therapeutics by 25.0% during the first quarter. Wasatch Advisors LP now owns 3,174,002 shares of the company’s stock valued at $28,185,000 after acquiring an additional 635,370 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of Nurix Therapeutics by 14.7% during the third quarter. ARK Investment Management LLC now owns 2,593,047 shares of the company’s stock valued at $20,381,000 after acquiring an additional 331,976 shares during the last quarter. State Street Corp raised its holdings in shares of Nurix Therapeutics by 9.2% during the third quarter. State Street Corp now owns 2,312,224 shares of the company’s stock valued at $30,128,000 after acquiring an additional 195,453 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of Nurix Therapeutics by 59.6% during the second quarter. FMR LLC now owns 1,790,655 shares of the company’s stock valued at $22,688,000 after acquiring an additional 668,632 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have commented on NRIX shares. Royal Bank of Canada increased their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday. Wells Fargo & Company cut their price target on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, February 16th. HC Wainwright cut their price target on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 9th. Finally, Robert W. Baird increased their price target on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $21.33.

Nurix Therapeutics Stock Performance

NRIX opened at $16.74 on Friday. Nurix Therapeutics, Inc. has a one year low of $4.22 and a one year high of $18.12. The business’s 50-day simple moving average is $12.64 and its 200-day simple moving average is $9.27. The stock has a market capitalization of $822.77 million, a P/E ratio of -6.29 and a beta of 2.06.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The business had revenue of $15.16 million during the quarter, compared to analysts’ expectations of $30.66 million. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -3.26 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $10.02, for a total value of $68,256.24. Following the sale, the chief financial officer now owns 68,333 shares of the company’s stock, valued at approximately $684,696.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 10,817 shares of company stock valued at $100,256. 7.20% of the stock is owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.